178 results about "Crohn disease" patented technology

The subject invention pertains to materials and methods for the prevention and treatment of gastrointestinal diseases, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Therapeutic compositions of the invention include compositions that can neutralize hydrogen peroxide, such as reducing agents and oxidizing agents. In one embodiment, a therapeutic composition of the invention comprises a reducing agent such as sodium thiosulfate. Therapeutic compositions of the invention can optionally include compounds with antibacterial activity, compositions that inhibit bacterial adherence to cells and tissue, compositions that inhibits epithelial lipid peroxidation, compositions that add viscosity to a solution, compositions that inhibit most cells, and/or compositions that help to seal or repair tight junctions between cells of the colonic epithelium of the gastrointestinal tract. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient.

A pharmaceutical composition includes a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-S-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs.

The present invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease characterized by fibrostenosing disease by determining the presence or absence in an individual of a fibrostenosis-predisposing allele linked to a NOD2/CARD15 locus, where the presence of the fibrostenosis-predisposing allele is diagnostic of or predictive of susceptibility to the clinical subtype of Crohn's disease characterized by fibrostenosing disease. In a method of the invention, the clinical subtype of Crohn's disease can be, for example, characterized by fibrostenosing disease independent of small bowel involvement. The invention also provides a method of optimizing therapy in an individual by determining the presence or absence in the individual of a fibrostenosis-predisposing allele linked to a NOD2/CARD15 locus, diagnosing individuals in which the fibrostenosis-predisposing allele is present as having a fibrostenosing subtype of Crohn's disease, and treating the individual having a fibrostenosing subtype of Crohn's disease based on the diagnosis.

The present invention relates to the selection of a set of polymorphism makers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to IBD (ex: Chrohn's disease) and/or their response to a particular drug or drugs.

Methods of treatment for Crohn's disease and multiple sclerosis are disclosed. Also disclosed are methods for repositioning a pharmaceutical by selecting at least one target gene, gene product, or loci associated with the treatment of at least one first disease, trait, or phenotype by the pharmaceutical, identifying at least one second disease, trait, or phenotype associated with the least one target gene, gene product, or loci using genome-wide associated studies, and selecting at least one identified second disease, trait and/or phenotype based on step for treatment with the pharmaceutical.

The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.

The present invention provides diagnostic methods for inflammatory bowel disorders (e.g., Crohn's disease or ulcerative colitis) comprising assessing expression, structure and/or function of O-glycans in a sample from a subject, as well as antibodies to such molecules.

The invention discloses new medical application of bacillus coagulans, particularly relates to application of the bacillus coagulans in preparing a medicine for treating an inflammatory bowel disease. The inflammatory bowel disease refers to ulcerative colitis and a crohn disease; the bacillus coagulans is selected but not limited from the bacillus coagulans preserved in the The China General Microbiological Culture Collection Center (CGMCC) with the preservation number of 1207. The bacillus coagulans has outstanding treatment effect when being used for treating the crohn disease as a medical active component and belongs to the field of biological medicines.

The invention discloses an application of an artemisinin derivative in preparation of medicament for treating Crohn disease, and the artemisinin derivative is selected from artesunate or artemether or styrene monomer 905 (SM905). The artemisinin derivative can be used for achieving the purpose of treating the Crohn disease by inhibiting Th1/Th17 immune response and inhibiting nuclear factor-kB activation. Compared with the existing medicaments, the artemisinin derivative has less and light side effects, in one year of following visits for the treatment of rheumatoid arthritis, transient reticulocyte decline and hepatic dysfunction only occur in individual cases, and the health can be restored by liver protection treatment without medicament withdrawal. Therefore, the artemisinin derivative can be taken by patients for a long time, the treatment can be maintained, and the purpose of effective treatment can be achieved.

A method is disclosed for determining whether a human having Crohn's disease is likely to respond to a therapy targeting a TNFSF member or a cytokine by measuring the level of certain mRNAs in response to a stimulus. A method of evaluating the effectiveness of a Crohn's disease therapy in a human is also disclosed. Furthermore, a method of screening compounds for use in the treatment of Crohn's disease is disclosed. A method of monitoring the disease state over time in Crohn's disease patients is also disclosed.

Disclosed are methods for diagnosing and prognosing Inflammatory Bowel disease or Crohn's disease (CD) by measuring levels of antibodies to glycans in a biological sample.

The present invention discloses a new medicine purpose of Clostridium butyricum and Bacillus coagulans, in particular relates to an application of Clostridium butyricum and Bacillus coagulans in preparing the medicine for curing inflammatory bowel diseases. The inflammatory bowel disease refers to an ulcerative colitis and a Crohn disease. The Clostridium butyricum is selected from but not limited to Clostridium butyricum, CGMCC and the preservation number is 0313.1; the Bacillus coagulans is selected from but not limited to Bacillus coagulans, CGMCC and the preservation number is 1270. The Clostridium butyricum and Bacillus coagulans as a single pharmaceutical active ingredient or a combined pharmaceutical active ingredient has significant curative effect on ulcerative colitis and Crohn's disease, pertaining to the art of biological medicine.

Methods of treating, reducing, or preventing a disease or symptom relating to a disease such as oral mucositis, gingivitis, periodontitis, gastric mucositis, inflammatory fibrosis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, inflammation associated with cancer, cancer treatment, or radiation, and/or pain that include: identifying a patient in need of treatment; and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.

The invention discloses an enteroscopy Crohn's disease auxiliary diagnosis system and method based on deep learning. The system comprises an enteroscopy image automatic acquisition subsystem, a database, a client and a server. The enteroscope image automatic acquisition subsystem is used for acquiring an enteroscope image; wherein the database comprises a sample set for training the convolutionalneural network; and the client is used for uploading the enteroscopy image acquired by the enteroscopy image automatic acquisition subsystem to the server, and receiving and displaying an analysis result fed back by the server. According to the method, an image recognition technology is utilized to monitor an endoscope video in real time, images containing key organ parts and suspicious Crohn focus areas are automatically collected, and after global preferences are made according to a weighting algorithm, whether the image is Crohn disease or not is diagnosed. According to the method, after the neural network model is utilized to automatically screen the images, the most valuable image can be extracted from the global video, auxiliary diagnosis is given, and more reliable and efficient support is provided for doctors to diagnose.

Methods of identifying Crohn's disease patients who may require early surgery and/or who are susceptible to developing complications during the course of disease. Anti-laminarin (anti-L) and anti-chitin (anti-C) antibodies, both independently and combined, can serve as diagnostic and prognostic indices for Crohn's disease.